[144] Haemonetics Corporation SEC Filing

Rhea-AI Filing Summary

Haemonetics Corporation Form 144 Notice details a proposed sale of 18,630 shares of common stock with an aggregate market value of $1,396,132.20 through Fidelity Brokerage Services on the NYSE, planned for June 26, 2025.

The shares were acquired through multiple restricted stock vestings between 2020-2025:

• 2020-2022: 469 shares total from two vestings
• 2023: 4,455 shares from three vestings
• 2025: 13,706 shares from four recent vestings

The filing also discloses a previous sale by Josep L. Llorens of 1,547 shares on May 19, 2025, generating proceeds of $107,319.26. All shares were acquired as compensation through restricted stock vestings, representing approximately 0.04% of the total 48,036,996 shares outstanding.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	18630	1396132.20	48036996	06/26/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/04/2020	Restricted Stock Vesting	Issuer			234	09/04/2020	Compensation
Common	09/04/2022	Restricted Stock Vesting	Issuer			235	09/04/2022	Compensation
Common	05/14/2023	Restricted Stock Vesting	Issuer			270	05/14/2023	Compensation
Common	05/16/2023	Restricted Stock Vesting	Issuer			766	05/16/2023	Compensation
Common	05/18/2023	Restricted Stock Vesting	Issuer			3419	05/18/2023	Compensation
Common	05/15/2025	Restricted Stock Vesting	Issuer			7630	05/15/2025	Compensation
Common	05/16/2025	Restricted Stock Vesting	Issuer			820	05/16/2025	Compensation
Common	05/17/2025	Restricted Stock Vesting	Issuer			4720	05/17/2025	Compensation
Common	05/18/2025	Restricted Stock Vesting	Issuer			536	05/18/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Josep L. Llorens 125 Summer Street Boston MA 02110	Common	05/19/2025	1547	107319.26

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many shares of HAE stock are being sold according to the June 2025 Form 144?

According to the Form 144 filing, 18,630 shares of HAE common stock are proposed to be sold through Fidelity Brokerage Services LLC, with an aggregate market value of $1,396,132.20.

When did the HAE insider acquire these shares being sold?

The shares were acquired through multiple restricted stock vestings between 2020-2025, with the largest portions vesting in May 2025: 7,630 shares on May 15, 4,720 shares on May 17, and other smaller vestings throughout May 2025. Earlier vestings occurred in 2020, 2022, and 2023.

What was the most recent insider sale of HAE stock prior to this Form 144?

According to the filing, Josep L. Llorens sold 1,547 shares of HAE common stock on May 19, 2025, generating gross proceeds of $107,319.26.

What is the total number of HAE shares outstanding as of June 2025?

According to the Form 144 filing, Haemonetics Corporation (HAE) had 48,036,996 shares outstanding at the time of the filing.

How were the HAE shares being sold originally acquired?

All shares were acquired through restricted stock vestings as compensation from the issuer (Haemonetics Corporation) over multiple dates between 2020-2025. No cash payment was required as these were compensation awards.